ReviewsReviews on Current Liquid Biopsy for Detection and Management of Pancreatic CancersKaczor-Urbanowicz, Karolina Elżbieta DMD, PhD, MSc∗,†,‡,§; Cheng, Jordan DDS∗,†; King, Jonathan C. MD∥; Sedarat, Alireza MD¶; Pandol, Stephen J. MD#,∗∗; Farrell, James J. MD††; Wong, David T.W. DMD, DMSc∗,†,‡‡; Kim, Yong PhD∗,†Author Information From the ∗Center for Oral and Head/Neck Oncology Research †Division of Oral Biology and Medicine ‡Section of Orthodontics, UCLA School of Dentistry §Institute for Quantitative and Computational Biosciences, UCLA, Los Angeles Departments of ∥Surgery ¶Gastroenterology, Ronald Reagan UCLA Medical Center, Santa Monica #Department of Medicine, Cedars-Sinai Medical Center ∗∗Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA ††Center for Pancreatic Diseases, Yale University, New Haven, CT ‡‡Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA. Received for publication February 27, 2020; accepted July 20, 2020. Address correspondence to: Yong Kim, PhD, Division of Oral Biology and Medicine, UCLA School of Dentistry, 73-022 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-1668 (e-mail: [email protected]); or David T.W. Wong, DMD, DMSc, Center for Oral/Head and Neck Oncology Research or Division of Oral Biology and Medicine, UCLA School of Dentistry, 10833 Le Conte Ave, 73-017 CHS, Los Angeles, CA 90095-1668 (e-mail: [email protected]). This work was supported by the Hirshberg Foundation for Pancreatic Cancer Research, Public Health Service grants from the National Institutes of Health (UH3 TR000923 and UG3 TR002978), 2017/18 Debbie's Dream Foundation — American Association for Cancer Research Gastric Cancer Research Fellowship (grant number 17-40-41- KACZ), and the QCBio Collaboratory Fellowship 2019/2020 from the Institute for Quantitative and Computational Biosciences at the University of California, Los Angeles (K.E.K.-U.). In addition, we are grateful for the donation (2017) and postdoctoral fellowship (2019/2020) funded by the Ronnie James Dio Stand Up and Shout Cancer Fund. In addition, we acknowledge the support from the Canadian Institute of Health Doctoral Foreign Student Award and Tobacco Related Disease Research Program Predoctoral Fellowship (J.C.). D.T.W.W. is a consultant to GlaxoSmithKlein, Absolutyes, Wrigley, and Colgate-Palmolive. None of the other authors have a conflict of interest in relation to this study. Pancreas: October 2020 - Volume 49 - Issue 9 - p 1141-1152 doi: 10.1097/MPA.0000000000001662 Buy Metrics Abstract Pancreatic cancer is the fourth leading cause of cancer death in the United States. Pancreatic cancer presents dismal clinical outcomes in patients, and the incidence of pancreatic cancer has continuously increased to likely become the second most common cause of cancer-related deaths by as early as 2030. One of main reasons for the high mortality rate of pancreatic cancer is the lack of tools for early-stage detection. Current practice in detecting and monitoring therapeutic response in pancreatic cancer relies on imaging analysis and invasive endoscopic examination. Liquid biopsy–based analysis of genetic alterations in biofluids has become a fundamental component in the diagnosis and management of cancers. There is an urgent need for scientific and technological advancement to detect pancreatic cancer early and to develop effective therapies. The development of a highly sensitive and specific liquid biopsy tool will require extensive understanding on the characteristics of circulating tumor DNA in biofluids. Here, we have reviewed the current status of liquid biopsy in detecting and monitoring pancreatic cancers and our understanding of circulating tumor DNA that should be considered for the development of a liquid biopsy tool, which will greatly aid in the diagnosis and healthcare of people at risk. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.